I’m 25, and I’ve begun developing pressure sores because I no longer have the strength to turn over by myself.
It hurts, and it’s hard not to feel embarrassed. Duchenne muscular dystrophy has already taken my ability to walk. Now my arms and hands are at risk. The disease steadily strips away independence, and every month without access to treatment gives it more time to do that.
I’m not demanding a cure or a guarantee, and I’m not insisting that any particular medicine be approved. I’m asking the government to follow through on what it has promised.
After Democrats’ gains in the midterms, they will control Congress starting in January, while a Republican remains in the White House. People with rare diseases shouldn’t have to spend another two years caught in partisan stalemate over something that ought to matter to both parties.
The Trump administration has a chance to show that its pledges to rare-disease patients are more than words. The FDA is due to decide by November 22 whether to approve deramiocel, an experimental treatment that might help people with Duchenne retain use of their arms and hands.
The decision also points to a broader problem: Can Washington establish a fair, consistent process for reviewing promising treatments, with clear expectations for the evidence required? When those expectations change late in the process, the impact isn’t limited to drug companies. Patients are left waiting as their conditions worsen.
In May, President Trump removed FDA Commissioner Marty Makary after a period of upheaval at the agency. Patients and drug developers had criticized the FDA’s handling of rare-disease treatments, including decisions to reject applications or require more studies.
Since then, the administration has made reforming rare-disease reviews a stated priority. In October, the FDA announced an initiative to develop standards that account for small patient groups and the distinct nature of each disease. Health and Human Services Secretary Robert F. Kennedy Jr. has said that rare conditions can’t be handled as though they’re all the same.
He’s right. My family can’t afford a system that does that.
My brother also has Duchenne. He received deramiocel for a period, and his condition improved while he was taking it. He later had to stop. That experience makes the FDA’s decision deeply personal for me, though it isn’t the only reason to consider the treatment. The agency also has clinical evidence to review.
An analysis of the Phase 3 HOPE-3 trial, published in a medical journal, found that patients given deramiocel lost upper-body function at about half the rate of those who received a placebo. Later data released by the company suggested that patients who switched from placebo to the treatment also experienced a slower decline. That offers some hope to people like me.
My arm strength affects whether I can feed myself, steer my wheelchair, use my phone, or keep running my business. When Duchenne takes those abilities, they don’t return.
The FDA rejected an earlier application in 2025. Then, in July, an advisory committee voted 9-3 that the evidence did not prove the treatment worked against heart disease associated with Duchenne. That was a different issue from the upper-limb outcomes emphasized in the revised application. After the company provided additional data, the FDA extended its review by three months.
FDA reviewers have also questioned changes to the trial’s statistical analysis and whether the results are enough to establish that the treatment works. Those questions deserve answers. Patients aren’t asking the agency to drop scientific standards or approve every drug. We want the standards laid out early, applied consistently, and explained openly.
A peer-reviewed Phase 3 study suggesting a possible benefit for people with a fatal disease deserves a serious and transparent review. The administration has said the FDA’s approach to rare diseases needs to improve. The November 22 decision is an opportunity to show what that means.
The Senate should confirm the next FDA commissioner and make sure that person carries out the administration’s commitments to people with rare diseases.
Congress doesn’t have to sit back and wait for the FDA. It could move forward with Right to Try 2.0, which would broaden access to experimental treatments suited to individual patients. It could also consider legislation from Sen. Ted Cruz to create a route for certain medicines and treatments approved by trusted foreign regulators to reach patients in the United States. The incoming Democratic majorities should work with the White House on these proposals.
Washington may be focused on the midterms and control of Congress. Families like mine can’t wait for another election, or for a government controlled by a single party. Duchenne takes more from me every month. Each year without progress means more people lose abilities they may never get back.
I’m not asking for a cure, a guarantee, or the approval of one particular drug. I’m asking the government to do what it says it will. I’ve already lost the use of my legs. I’m trying to hold on to my arms and hands.
President Trump has heard from us, and the new Congress has a chance to support us. On November 22, the FDA can show what its promises to people with rare diseases mean in practice.






